Last reviewed · How we verify

Genocea Biosciences, Inc. — Portfolio Competitive Intelligence Brief

Genocea Biosciences, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. CancerVax Corporation · 1 shared drug class
  2. Centre Leon Berard · 1 shared drug class
  3. Chiang Mai University · 1 shared drug class
  4. Chiltern Pesquisa Clinica Ltda · 1 shared drug class
  5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
  6. Galena Biopharma, Inc. · 1 shared drug class
  7. GlaxoSmithKline · 1 shared drug class
  8. Green Cross Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genocea Biosciences, Inc.:

Cite this brief

Drug Landscape (2026). Genocea Biosciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genocea-biosciences-inc. Accessed 2026-05-16.

Related